Shares of Akso Health Group Sponsored ADR (NASDAQ:AHG – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $1.52, but opened at $1.42. Akso Health Group shares last traded at $1.54, with a volume of 787 shares trading hands.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the company. Wall Street Zen upgraded Akso Health Group to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Akso Health Group in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.
Read Our Latest Analysis on AHG
Akso Health Group Stock Performance
Institutional Investors Weigh In On Akso Health Group
A hedge fund recently bought a new stake in Akso Health Group stock. SmartHarvest Portfolios LLC acquired a new position in shares of Akso Health Group Sponsored ADR (NASDAQ:AHG – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 16,748 shares of the company’s stock, valued at approximately $27,000. 1.21% of the stock is owned by institutional investors.
About Akso Health Group
Akso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. It also offers consultancy and information technology support services; provides health treatment services; sells medical devices; and trades in branded products, as well as promotes products. The company was formerly known as Xiaobai Maimai Inc and changed its name to Akso Health Group in December 2021.
Further Reading
- Five stocks we like better than Akso Health Group
- One Short- and One Long-Term ETF for Quantum Computing Bulls
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
- Why Micron Is Doubling Down While the HBM Shortage Persists
- China’s Helium Ban Could Reshape the AI Supply Chain
Receive News & Ratings for Akso Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akso Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
